Low Dose Naltrexone Prescribing Practices for Children and Adolescents with Long COVID

This retrospective study of 62 pediatric and young adult patients with long COVID describes real-world prescribing patterns for low-dose naltrexone, revealing it was primarily used for those with severe fatigue and neurocognitive symptoms, was generally well-tolerated, and underscores the need for controlled clinical trials to establish its efficacy.

The Gist

Imagine your body is a highly sophisticated security system. When a child gets the virus that causes COVID-19, it's like a burglar breaking into the house. Usually, the security system (the immune system) kicks the burglar out, and the house goes back to normal.

But for some kids, the burglar leaves, and the security system gets confused. It keeps screaming "Intruder!" even though the house is empty. This constant, false alarm causes the body to feel exhausted, foggy, dizzy, and in pain. This is Long COVID.

Right now, doctors don't have a specific "off switch" for this confused alarm system. They have to try different things to calm it down. One of the tools they are trying is a medication called Low-Dose Naltrexone (LDN).

Here is what this new study tells us about using LDN for kids, explained simply:

1. What is LDN? (The "Volume Knob" Analogy)

Think of Naltrexone as a volume knob for the body's pain and inflammation signals.

• High Dose: If you turn the knob all the way up (the standard 50mg dose used for addiction), it mutes the signal completely. It shuts the system down.
• Low Dose (LDN): This study looked at turning the knob just a tiny bit (1.5mg to 4.5mg). The theory is that this tiny nudge doesn't shut the system off; instead, it "resets" the alarm. It tricks the body into calming down its own inflammation, like a gentle tap on the shoulder to say, "Hey, relax, the coast is clear."

2. Who Did They Study?

The researchers looked at 62 kids and young adults (ages 8 to 23) from three different top-tier hospitals in the US. These weren't just any kids; these were the ones who had been struggling with Long COVID for a long time and hadn't gotten better with rest or therapy alone.

The "Symptom Soup":
Almost every single kid in this group was suffering from:

• Extreme Fatigue: Like running a marathon every day just to get out of bed.
• Brain Fog: Like trying to think through a thick fog.
• Headaches and Dizziness.
• Anxiety.

3. What Happened When They Took the Medicine?

The study didn't prove that LDN cures Long COVID (that would require a strict scientific experiment with a fake pill, which they didn't do here). Instead, they just watched what happened in the real world.

• It's Safe: The medicine was generally well-tolerated. About 7 out of 10 kids had no side effects at all.
• The "Dream" Side Effect: The most common complaints were vivid dreams or trouble sleeping. Imagine your brain is a movie theater that won't stop playing intense, colorful movies at night. This happened to about 1 in 10 kids.
• Did it Work? About two-thirds of the kids (66%) decided to keep taking the medicine.
  • Why did the other third stop? Mostly because they felt it wasn't helping them enough, or because of the side effects.
  • Interestingly, some kids felt worse when they stopped taking it, suggesting the medicine was doing something to help them.

4. The "Who" and "Why" of Prescribing

The doctors weren't giving this medicine to everyone. They were like gardeners choosing the right tool for the right plant. They mostly prescribed LDN to kids who had:

• Severe fatigue.
• Trouble thinking (brain fog).
• Dizziness (autonomic issues).

It seems LDN is being used as a targeted tool for the kids whose "security systems" are most chaotic in those specific areas.

5. The Big Takeaway

Think of this study as a field report from the front lines.

• Good News: LDN appears to be safe for kids. It doesn't seem to cause major harm, and many families are sticking with it because they feel it helps.
• The Missing Piece: We still don't know for sure if it works better than a placebo (a sugar pill). We need a bigger, more controlled experiment to prove it.
• The Future: This study gives doctors the confidence to say, "It's safe to try," and it gives scientists the data they need to design the perfect experiment to see if it actually cures the symptoms.

In a nutshell: This paper is a "safety check" and a "usage guide." It tells us that using this low-dose medicine for kids with Long COVID is generally safe, mostly helps with fatigue and brain fog, and is worth studying further to see if it can truly turn off that confusing alarm system.

Technical Summary

1. Problem Statement

Pediatric Long COVID (Post-Acute Sequelae of SARS-CoV-2 Infection, or PASC) presents a significant clinical challenge characterized by a high burden of symptoms including fatigue, neurocognitive dysfunction, and autonomic instability. Currently, there are no FDA-approved pharmacologic treatments for pediatric Long COVID. While Low-Dose Naltrexone (LDN) has shown promise in adult populations and other pediatric conditions (e.g., Crohn's disease, chronic pain) due to its potential immunomodulatory and anti-inflammatory properties, there is a critical evidence gap regarding its safety, tolerability, and prescribing patterns in children and adolescents. This study aims to fill that gap by describing real-world clinical practices.

2. Methodology

• Study Design: A multicenter, retrospective case series.
• Setting: Three specialized pediatric Long COVID programs in the United States:
  • Kennedy Krieger Institute (Baltimore, MD)
  • Children's National Hospital (Washington, DC)
  • Children's Hospital Los Angeles (Los Angeles, CA)
• Participants: 62 patients aged ≤25 years with a clinical diagnosis of Long COVID who were prescribed LDN between July 2020 and July 2025.
• Data Collection: Deidentified data were extracted from electronic medical records (EMR).
  • Variables: Demographics, comorbidities, symptom prevalence, LDN dosing (start, titration, maintenance), treatment duration, discontinuation reasons, and adverse events.
  • Outcome Measures: Standardized patient-reported outcomes (PROs) including the PedsQL™ (Generic Core and Fatigue Scales) and PROMIS® (Physical functioning, Cognitive functioning, Fatigue, Pain interference).
• Statistical Analysis: Descriptive statistics (counts, percentages, means, standard deviations) were used to summarize demographics, symptom burdens, and treatment patterns. No inferential statistics for efficacy were performed as the study was not powered for efficacy assessment.

3. Key Contributions

• First Large-Scale Pediatric LDN Cohort: This is one of the largest retrospective analyses specifically focusing on LDN use in pediatric Long COVID patients across multiple US sites.
• Characterization of Prescribing Patterns: The study defines the typical patient profile for LDN initiation (severe fatigue, neurocognitive symptoms, autonomic dysfunction) and standard dosing protocols (titration to 4.5 mg/day).
• Safety Profile Documentation: It provides empirical data on the tolerability of LDN in a young population, distinguishing between medication side effects and underlying Long COVID symptoms.
• Baseline Severity Quantification: The study utilizes PROs to establish that patients prescribed LDN in this cohort had significantly impaired baseline quality of life compared to general population norms.

4. Key Results

Demographics and Clinical Profile

• Cohort: 62 patients (Mean age: 15.6 years; 53.2% male).
• Comorbidities: 67.7% had at least one pre-existing condition. Most common were anxiety (24.2%), ADHD (22.6%), asthma (12.9%), and depression (11.3%).
• Symptom Burden:
  • Fatigue: 98.4% (nearly universal).
  • Headaches: 87.1%.
  • Brain Fog: 74.2%.
  • Dizziness/Lightheadedness: 67.7%.
  • Anxiety: 66.1%.
  • Post-Exertional Malaise (PEM): 56.5%.
  • Note: LDN-treated patients showed higher prevalence of neurocognitive and autonomic symptoms compared to the general clinic cohorts at the same sites.

Treatment Patterns

• Timing: Mean time from infection/symptom onset to LDN initiation was 21.6 months (Median: 20 months).
• Dosing:
  • Most common maintenance dose: 4.5 mg/day (71.0%).
  • Other doses: 1.5 mg (11.3%) and 3.0 mg (9.7%).
  • Titration was gradual, starting typically at 1.5 mg.
• Retention: 66.1% of patients remained on LDN at the time of data collection.
• Discontinuation: 25.8% discontinued.
  • Primary reason: Perceived lack of benefit (43.8%).
  • Secondary reason: Side effects (25.0%).
  • Tertiary reason: Symptom resolution (18.8%).

Safety and Tolerability

• Adverse Events: 71.0% of patients reported no adverse effects.
• Common Side Effects: Vivid dreams/nightmares (9.7%) and insomnia (9.7%).
• Overlap: Some reported side effects (fatigue, headaches, dizziness) overlapped with Long COVID symptoms, making attribution difficult. However, new-onset insomnia and vivid dreams were clearly linked to LDN.

Quality of Life (Baseline)

Patients exhibited severe impairment at the time of LDN initiation:

• PedsQL: Physical Health Summary Score (M=38.0); Multidimensional Fatigue (M=35.7).
• PROMIS®:
  • Physical Functioning: Significantly below norms (M≈36.8).
  • Cognitive Functioning: Reduced (M≈40.8).
  • Fatigue: Significantly elevated (M=68.0).
  • Pain Interference: Elevated (M=58.6).

5. Significance and Interpretation

• Clinical Utility: LDN appears to be a generally well-tolerated therapeutic option for pediatric Long COVID, particularly for patients with prominent fatigue, neurocognitive symptoms, and autonomic dysfunction.
• Real-World Evidence: The study validates that clinicians are currently using LDN for severe, refractory cases (average 2 years post-infection) after non-pharmacologic interventions failed.
• Limitations:
  • Retrospective Nature: Lack of a control group prevents efficacy conclusions.
  • Confounding: Difficulty distinguishing LDN side effects from fluctuating Long COVID symptoms.
  • Availability: LDN requires compounding pharmacies, which may limit accessibility and standardization (fillers/absorption rates vary).
• Future Directions: The authors emphasize the urgent need for randomized, placebo-controlled clinical trials (such as those planned under the NIH RECOVER-TLC initiative) to systematically evaluate efficacy, optimal dosing, and age-specific side effect profiles.

Conclusion: While this study does not prove efficacy, it provides crucial descriptive evidence that LDN is being utilized safely in a specialized pediatric Long COVID population with high symptom burdens, supporting the rationale for further rigorous clinical investigation.